A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia
Status:
Unknown status
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The aim of the present study is to evaluate the efficacy and safety of MK-0683 in the
treatment of PV and ET. This agent has most recently been shown to be a potent inhibitor of
the autonomous proliferation of haematopoietic cells of PV and ET patients carrying the JAK2
V617F mutation. Accordingly, it may be anticipated that MK-0683 - by decreasing the JAK2
allele burden - may influence clonal myeloproliferation and in vivo granulocyte, platelet and
endothelial activation , which are considered to be major determinants of morbidity and
mortality ( thrombosis, bleeding, extramedullary haematopoiesis , myelofibrosis ) in these
disorders. The effects of MK-0683 at the molecular level will be studied by global/ focused
gene expression profiling, epigenome profiling and proteomics.